Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Local veterinary ... in an investigational study of donor stem cells for ... stem cell therapy and has performed clinical stem cell ... study is to determine if a single injection of ... joints can help reduce pain and inflammation in the ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
(Date:10/19/2014)... 2014 The Asia-Pacific Bromine Market ... Asia-Pacific with analysis and forecast of revenue. , ... Bromine Market report, to get an idea of ... glimpse of the segmentation in the Asia-Pacific bromine ... figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... , , , ... the leading systems biology tools company, announced today that it ... cells with global pharmaceutical companies and leading academic centers as ... base" on development and biology of different types of stem ...
... ... Trial (NLST). , ... 31, 2009 -- The Honolulu-based Pacific Health Research Institute (PHRI) has received $2.8 million ... Trial (NLST), a major lung cancer screening study in Hawaii, for two more years. ...
... September 1 According to a new,market research report, ... the total global,biomaterials market is expected to be worth ... from 2009 to 2014. The U.S. market is expected ... biomaterials market today has,already crossed $28 billion. , ...
Cached Biology Technology:GeneGo Kicks Off The MetaMiner Stem Cell Project With Industry and Academics 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3Global Biomaterials Market Worth US$58.1 Billion by 2014 2Global Biomaterials Market Worth US$58.1 Billion by 2014 3
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
(Date:10/14/2014)... likely takes between 10 and 20 years to ... window" of intervention if detected early, which may ... say Australian clinical researchers. , Dr Jeremy ... Institute of Medical Research, analysed medical histories and ... pancreatic cancer patients, operated on between 1994 and ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Early detection window when pancreatic cancer is in the family 2
... of Chicago scientists have successfully used geometrically patterned surfaces ... approach is a departure from that of many stem-cell ... proteins in controlling the fate of stem cells. ... both cases it,s the shape alone that,s dictating whether ...
... This release is available in French . ... on an extremely important process for the proper functioning ... transportation pathway of ,cargo, to and from the surface ... have severe consequences, leading to numerous diseases such as ...
... release is available in French . ... in contact with bacteria, inducing an inflammatory response that is ... and this can lead to inflammatory bowel disease that may ... the mechanism of inflammation, has long been believed to be ...
Cached Biology News:Getting turned on 2Getting turned on 3Could regulating intestinal inflammation prevent colon cancer? 2
... This marking pen has been designed to provide a ... the specimen on a slide. This barrier creates ... within the target area on the slide. PAP ... alcohol and acetone. It can be removed, if ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
...
Anti-Conjugated Quinaldic Acid...
Biology Products: